Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Rowe

Showing results (541-550 of 632) with videos related to

Pageof 64
Sort By:
European Journal of Human Genetics : EJHG|August 10, 1999
Non-random distribution of mutations in the PHEX gene, and under-detected missense mutations at non-conserved residuesD Filisetti, G Ostermann, M von Bredow, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 5, 2023
SUVPhilipp E Hartrampf, Thomas Hüttmann, Anna Katharina Seitz, et al.
Molecular Oncology|August 17, 2018
From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world settingSteven P Rowe, Brandon Luber, Monique Makell, et al.
Advances in Radiation Oncology|April 14, 2020
Online Prostate-Specific Membrane Antigen and Positron Emission Tomography-Guided Radiation Therapy for Oligometastatic Prostate CancerWilliam T Hrinivich, Ryan Phillips, Angela J Da Silva, et al.
The Journal of Urology|October 18, 2024
Clinical Factors Associated With Suspicious <sup>18</sup>F-DCFPyL Prostate-Specific Membrane Antigen Positron Emission Tomography Activity in Patients Initially Managed With Radical Prostatectomy Including Prostate-Specific Antigen < 0.5 ng/mLEric V Li, Richard Bennett, Austin Ho, et al.
Molecular Imaging and Biology|July 30, 2024
Imaging of Chromophobe Renal Cell Carcinoma with <sup>99m</sup>Tc-Sestamibi SPECT/CT: Considerations Regarding Risk Stratification and Histologic ReclassificationSteven P Rowe, Salikh Murtazaliev, Jorge D Oldan, et al.
Prostate Cancer and Prostatic Diseases|October 16, 2019
A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancerAshley E Ross, Paula J Hurley, Phuoc T Tran, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 14, 2017
Predictive Value of <sup>18</sup>F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with VandetanibRudolf A Werner, Jan-Stefan Schmid, Takahiro Higuchi, et al.
Nuclear Medicine Communications|February 22, 2023
Wnt/β-catenin modulating drugs regulate somatostatin receptor expression and internalization of radiolabelled octreotide in neuroendocrine tumor cellsAlexander Weich, Dorothea Rogoll, Melissa Peschka, et al.
Annals of Nuclear Medicine|October 26, 2017
Low levels of PSMA expression limit the utility of <sup>18</sup>F-DCFPyL PET/CT for imaging urothelial carcinomaScott P Campbell, Alexander S Baras, Mark W Ball, et al.
Pageof 64

Showing results (541-550 of 632) with videos related to

Sort By:
Pageof 64
European Journal of Human Genetics : EJHG|August 10, 1999
Non-random distribution of mutations in the PHEX gene, and under-detected missense mutations at non-conserved residuesD Filisetti, G Ostermann, M von Bredow, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 5, 2023
SUVPhilipp E Hartrampf, Thomas Hüttmann, Anna Katharina Seitz, et al.
Molecular Oncology|August 17, 2018
From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world settingSteven P Rowe, Brandon Luber, Monique Makell, et al.
Advances in Radiation Oncology|April 14, 2020
Online Prostate-Specific Membrane Antigen and Positron Emission Tomography-Guided Radiation Therapy for Oligometastatic Prostate CancerWilliam T Hrinivich, Ryan Phillips, Angela J Da Silva, et al.
The Journal of Urology|October 18, 2024
Clinical Factors Associated With Suspicious <sup>18</sup>F-DCFPyL Prostate-Specific Membrane Antigen Positron Emission Tomography Activity in Patients Initially Managed With Radical Prostatectomy Including Prostate-Specific Antigen < 0.5 ng/mLEric V Li, Richard Bennett, Austin Ho, et al.
Molecular Imaging and Biology|July 30, 2024
Imaging of Chromophobe Renal Cell Carcinoma with <sup>99m</sup>Tc-Sestamibi SPECT/CT: Considerations Regarding Risk Stratification and Histologic ReclassificationSteven P Rowe, Salikh Murtazaliev, Jorge D Oldan, et al.
Prostate Cancer and Prostatic Diseases|October 16, 2019
A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancerAshley E Ross, Paula J Hurley, Phuoc T Tran, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 14, 2017
Predictive Value of <sup>18</sup>F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with VandetanibRudolf A Werner, Jan-Stefan Schmid, Takahiro Higuchi, et al.
Nuclear Medicine Communications|February 22, 2023
Wnt/β-catenin modulating drugs regulate somatostatin receptor expression and internalization of radiolabelled octreotide in neuroendocrine tumor cellsAlexander Weich, Dorothea Rogoll, Melissa Peschka, et al.
Annals of Nuclear Medicine|October 26, 2017
Low levels of PSMA expression limit the utility of <sup>18</sup>F-DCFPyL PET/CT for imaging urothelial carcinomaScott P Campbell, Alexander S Baras, Mark W Ball, et al.
Pageof 64